Kisqali and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Kisqali (ribociclib succinate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Letrozole, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Kisqali. It is created by eHealthMe based on reports of 25,037 people who have side effects when taking Kisqali from the FDA, and is updated regularly.

What is Kisqali?

Kisqali has active ingredients of ribociclib succinate. eHealthMe is studying from 25,050 Kisqali users. Check the latest studies of Kisqali.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,066 drugs and 915 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

25,037 people reported to have side effects when taking Kisqali.
Among them, 138 people (0.55%) have Neoplasm progression.

Could Kisqali cause Neoplasm progression?

Among these 138 people:

How long have people been on Kisqali when they have Neoplasm progression? *

Click here to view more results

What is the gender of people who have Neoplasm progression when taking Kisqali? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Kisqali and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kisqali:

Kisqali (25,050 reports)

Neoplasm progression treatments and more:

Neoplasm progression (41,778 reports)

How severe was Neoplasm progression and when was it recovered:

Neoplasm progression in Kisqali

Expand to all the drugs that have ingredients of ribociclib succinate:

Neoplasm progression and drugs with ingredients of ribociclib succinate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kisqali:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,066 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (915 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ribociclib succinate (the active ingredients of Kisqali) and Kisqali (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.